外周区域麻醉的局麻药辅助剂:叙述性综述
术后中重度疼痛持续时间常超过单次外周神经阻滞的时效,即使常规使用区域麻醉技术仍存在问题。局麻药辅助剂(同时静脉或神经周围注射药物)是简单策略,可能将阻滞获益延长至传统8-14小时上限以上。本综述汇总历史与新型辅助剂证据,并基于安全性考虑推荐全身用地塞米松0.1-0.2 mg.kg-1用于显著术后疼痛手术患者。
要点
- 神经周围地塞米松和右美托咪定分别最多延长镇痛平均时长8小时和6小时。
- 神经周围肾上腺素仅延长镇痛平均时长略超过1小时。
- 推荐全身用地塞米松0.1-0.2 mg.kg-1用于显著术后疼痛手术患者。
核心结论
- 神经周围地塞米松和右美托咪定能显著延长阻滞镇痛时长,但均未满足理想局麻药辅助剂全部标准。
- 基于神经肌肉损伤担忧及神经周围与全身途径优劣证据不一致,推荐全身用地塞米松作为局麻药辅助剂。
研究设计与样本
- 叙述性综述,未报告系统检索范围与样本量。
主要发现
- 与长效局麻药联用时,神经周围右美托咪定最多延长镇痛平均时长6小时。
- 与长效局麻药联用时,神经周围地塞米松最多延长镇痛平均时长8小时。
- 神经周围肾上腺素仅延长镇痛平均时长略超过1小时。
- 体外研究显示神经周围右美托咪定神经毒性效应结果矛盾。
- 右美托咪定副作用包括心动过缓、低血压和镇静,地塞米松轻度升高血糖。
关键数值与推荐
- 推荐全身用地塞米松作为局麻药辅助剂,剂量0.1-0.2 mg.kg-1,用于所有接受与显著术后疼痛相关手术的患者。
- 单次外周神经阻滞传统最大时效为8-14小时。
临床怎么用
- 对接受显著术后疼痛相关手术的患者,可考虑全身用地塞米松0.1-0.2 mg.kg-1以延长外周神经阻滞镇痛。
- 使用神经周围右美托咪定需警惕心动过缓、低血压和镇静。
- 使用地塞米松需注意轻度血糖升高。
局限性
- 神经周围右美托咪定体外神经毒性研究结果矛盾。
- 神经周围与全身途径给药的优越性缺乏一致证据。
- 神经周围右美托咪定和地塞米松均未满足理想局麻药辅助剂全部标准。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Moderate-to-severe postoperative pain persists for longer than the duration of single-shot peripheral nerve blocks and hence continues to be a problem even with the routine use of regional anaesthesia techniques. The administration of local anaesthetic adjuncts, defined as the concomitant intravenous or perineural injection of one or more pharmacological agents, is an attractive and technically simple strategy to potentially extend the benefits of peripheral nerve blockade beyond the conventional maximum of 8-14 hours. Historical local anaesthetic adjuncts include perineural adrenaline that has been demonstrated to increase the mean duration of analgesia by as little as just over 1 hour. Of the novel local anaesthetic adjuncts, dexmedetomidine and dexamethasone have best demonstrated the capacity to considerably improve the duration of blocks. Perineural dexmedetomidine and dexamethasone increase the mean duration of analgesia by up to 6 hour and 8 hour, respectively, when combined with long-acting local anaesthetics. The evidence for the safety of these local anaesthetic adjuncts continues to accumulate, although the findings of a neurotoxic effect with perineural dexmedetomidine during in-vitro studies are conflicting. Neither perineural dexmedetomidine nor dexamethasone fulfils all the criteria of the ideal local anaesthetic adjunct. Dexmedetomidine is limited by side-effects such as bradycardia, hypotension and sedation, and dexamethasone slightly increases glycaemia. In view of the concerns related to localised nerve and muscle injury and the lack of consistent evidence for the superiority of the perineural vs. systemic route of administration, we recommend the off-label use of systemic dexamethasone as a local anaesthetic adjunct in a dose of 0.1-0.2 mg.kg-1 for all patients undergoing surgery associated with significant postoperative pain.
引用
- Desai N, Kirkham KR, Albrecht E, et al. Local anaesthetic adjuncts for peripheral regional anaesthesia: a narrative review. Anaesthesia. 2021. PMID: 33426668. doi:10.1111/anae.15245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。